---
document_datetime: 2025-12-02 05:38:32
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/maviret.html
document_name: maviret.html
version: success
processing_time: 0.1194707
conversion_datetime: 2025-12-24 16:30:54.736202
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Maviret

[RSS](/en/individual-human-medicine.xml/66474)

##### Authorised

This medicine is authorised for use in the European Union

glecaprevir / pibrentasvir Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Maviret](#news-on)
- [More information on Maviret](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Maviret is an antiviral medicine used to treat adults and children from 3 years of age with chronic (long-term) hepatitis C, an infectious disease that affects the liver, which is caused by the hepatitis C virus.

Maviret contains the active substances glecaprevir and pibrentasvir.

Expand section

Collapse section

## How is Maviret used?

Maviret can only be obtained with a prescription, and treatment should be started and monitored by a doctor experienced in the management of patients with hepatitis C virus infection.

For adults, adolescents aged 12 and older, and children weighing at least 45 kg, Maviret is available as tablets that contain 100 mg glecaprevir and 40 mg pibrentasvir. The recommended dose is three tablets once a day. For children between 3 and 12 years old weighing between 12 and 45 kg, Maviret is available in sachets of granules that contain 50 mg glecaprevir and 20 mg pibrentasvir, with the recommended dose dependent on weight. Both tablets and granules should be taken with food and treatment lasts 8, 12 or 16 weeks.

The duration of treatment depends on the HCV variety (genotype), whether patients have liver cirrhosis (scarring of the liver) or whether they have received previous treatments with pegylated interferon and ribavirin, with or without sofosbuvir, or sofosbuvir and ribavirin (other medicines for hepatitis C).

For more information about using Maviret, see the package leaflet or contact your doctor or pharmacist.

## How does Maviret work?

The active substances in Maviret, glecaprevir and pibrentasvir, block two proteins essential for the hepatitis C virus to multiply. Glecaprevir blocks the action of a protein called NS3/4A protease, while pibrentasvir blocks a protein called NS5A. By blocking these proteins, Maviret stops the hepatitis C virus from multiplying and infecting new cells.

## What benefits of Maviret have been shown in studies?

There are 6 genotypes of the hepatitis C virus and Maviret has been shown to be effective at clearing all genotypes from the blood.

In 8 main studies involving over 2,300 adults with hepatitis C, 99% of patients with genotype 1, the most common genotype, without cirrhosis, tested negative for the virus after 8 weeks of Maviret treatment and 97% patients with genotype 1 with cirrhosis were negative after 8 or 12 weeks. A negative test result means that the virus was not found. Results were similar for genotypes 2 and 4-6. The medicine's effectiveness in clearing genotype 3 was slightly lower than for other genotypes (95%).

In a study in 47 children aged between 12 and 18 years with genotypes 1 to 4 and without cirrhosis, all patients tested negative for the virus after 12 weeks of treatment. The same study investigated the use of Maviret in children between the ages of 3 and 11 without cirrhosis and with genotypes 1-4 of the hepatitis C virus. It showed that 98% of the 62 participants who received the final recommended dose tested negative after 8 weeks if they had not previously taken other treatments or after 12 to 16 weeks if they had previously been using interferon treatments.

Results in children also showed that the way the medicine was absorbed, modified and removed from the body was similar to that in adults. Based on data available in adults, it is expected that Maviret is also effective in children with genotypes 5 and 6.

## What are the risks associated with Maviret?

The most common side effects with Maviret (which may affect more than 1 in 10 people) are headache and tiredness.

Maviret must not be used in patients with severely reduced liver function. It must also not be used together with certain medicines such as:

• atorvastatin, simvastatin (medicines for lowering cholesterol levels in the blood);

• dabigatran etexilate (a medicine for preventing blood clots);

• ethinyl estradiol-containing products (such as contraceptive medicines);

• rifampicin (antibiotic usually used to treat tuberculosis);

• carbamazepine, phenobarbital, phenytoin, primidone (medicines for epilepsy);

• St John's wort (a herbal remedy used for depression and anxiety).

For the full list of restrictions and side effects with Maviret, see the package leaflet.

## Why is Maviret authorised in the EU?

Maviret has been shown to be highly effective in clearing the hepatitis C virus from the blood, particularly in patients who have not been treated previously or who do not have cirrhosis. The fact that Maviret can be given without ribavirin and without dose adjustments in patients with severe kidney problems is a further advantage in comparison with similar medicines. With regard to its safety, Maviret's pattern of side effects raises no particular concern.

The European Medicines Agency therefore decided that Maviret's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Maviret?

The company that markets Maviret will carry out a study in patients who previously have had liver cancer to evaluate the risk of liver cancer returning after treatment with direct-acting antivirals such as Maviret. This study is being carried out in light of data suggesting that patients treated with medicines belonging to the same class as Maviret and who have had liver cancer could be at risk of their cancer returning early.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Maviret have also been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Maviret are continuously monitored. Side effects reported with Maviret are carefully evaluated and any necessary action taken to protect patients.

## Other information about Maviret

Maviret received a marketing authorisation valid throughout the EU on 26 July 2017.

Maviret : EPAR - Medicine overview

Reference Number: EMA/409726/2017

English (EN) (117.41 KB - PDF)

**First published:** 17/08/2017

**Last updated:** 28/07/2021

[View](/en/documents/overview/maviret-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-649)

български (BG) (168.3 KB - PDF)

**First published:**

17/08/2017

**Last updated:**

28/07/2021

[View](/bg/documents/overview/maviret-epar-medicine-overview_bg.pdf)

español (ES) (143.18 KB - PDF)

**First published:**

17/08/2017

**Last updated:**

28/07/2021

[View](/es/documents/overview/maviret-epar-medicine-overview_es.pdf)

čeština (CS) (167.96 KB - PDF)

**First published:**

17/08/2017

**Last updated:**

28/07/2021

[View](/cs/documents/overview/maviret-epar-medicine-overview_cs.pdf)

dansk (DA) (142.84 KB - PDF)

**First published:**

17/08/2017

**Last updated:**

28/07/2021

[View](/da/documents/overview/maviret-epar-medicine-overview_da.pdf)

Deutsch (DE) (147.55 KB - PDF)

**First published:**

17/08/2017

**Last updated:**

28/07/2021

[View](/de/documents/overview/maviret-epar-medicine-overview_de.pdf)

eesti keel (ET) (138.37 KB - PDF)

**First published:**

17/08/2017

**Last updated:**

28/07/2021

[View](/et/documents/overview/maviret-epar-medicine-overview_et.pdf)

ελληνικά (EL) (178.32 KB - PDF)

**First published:**

17/08/2017

**Last updated:**

28/07/2021

[View](/el/documents/overview/maviret-epar-medicine-overview_el.pdf)

français (FR) (145.11 KB - PDF)

**First published:**

17/08/2017

**Last updated:**

28/07/2021

[View](/fr/documents/overview/maviret-epar-medicine-overview_fr.pdf)

hrvatski (HR) (165.66 KB - PDF)

**First published:**

17/08/2017

**Last updated:**

28/07/2021

[View](/hr/documents/overview/maviret-epar-medicine-overview_hr.pdf)

italiano (IT) (142.68 KB - PDF)

**First published:**

17/08/2017

**Last updated:**

28/07/2021

[View](/it/documents/overview/maviret-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (181.87 KB - PDF)

**First published:**

17/08/2017

**Last updated:**

28/07/2021

[View](/lv/documents/overview/maviret-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (166.08 KB - PDF)

**First published:**

17/08/2017

**Last updated:**

28/07/2021

[View](/lt/documents/overview/maviret-epar-medicine-overview_lt.pdf)

magyar (HU) (165.51 KB - PDF)

**First published:**

17/08/2017

**Last updated:**

28/07/2021

[View](/hu/documents/overview/maviret-epar-medicine-overview_hu.pdf)

Malti (MT) (175.5 KB - PDF)

**First published:**

17/08/2017

**Last updated:**

28/07/2021

[View](/mt/documents/overview/maviret-epar-medicine-overview_mt.pdf)

Nederlands (NL) (143.8 KB - PDF)

**First published:**

17/08/2017

**Last updated:**

28/07/2021

[View](/nl/documents/overview/maviret-epar-medicine-overview_nl.pdf)

polski (PL) (168.96 KB - PDF)

**First published:**

17/08/2017

**Last updated:**

28/07/2021

[View](/pl/documents/overview/maviret-epar-medicine-overview_pl.pdf)

português (PT) (143.45 KB - PDF)

**First published:**

17/08/2017

**Last updated:**

28/07/2021

[View](/pt/documents/overview/maviret-epar-medicine-overview_pt.pdf)

română (RO) (165.05 KB - PDF)

**First published:**

17/08/2017

**Last updated:**

28/07/2021

[View](/ro/documents/overview/maviret-epar-medicine-overview_ro.pdf)

slovenčina (SK) (166.8 KB - PDF)

**First published:**

17/08/2017

**Last updated:**

28/07/2021

[View](/sk/documents/overview/maviret-epar-medicine-overview_sk.pdf)

slovenščina (SL) (165.66 KB - PDF)

**First published:**

17/08/2017

**Last updated:**

28/07/2021

[View](/sl/documents/overview/maviret-epar-medicine-overview_sl.pdf)

Suomi (FI) (141.34 KB - PDF)

**First published:**

17/08/2017

**Last updated:**

28/07/2021

[View](/fi/documents/overview/maviret-epar-medicine-overview_fi.pdf)

svenska (SV) (141.54 KB - PDF)

**First published:**

17/08/2017

**Last updated:**

28/07/2021

[View](/sv/documents/overview/maviret-epar-medicine-overview_sv.pdf)

Maviret : EPAR - Risk-management-plan summary

English (EN) (39.96 KB - PDF)

**First published:** 24/04/2019

**Last updated:** 16/02/2023

[View](/en/documents/rmp-summary/maviret-epar-risk-management-plan-summary_en.pdf)

## Product information

Maviret : EPAR - Product information

English (EN) (587.83 KB - PDF)

**First published:** 17/08/2017

**Last updated:** 02/03/2023

[View](/en/documents/product-information/maviret-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-31)

български (BG) (617.88 KB - PDF)

**First published:**

17/08/2017

**Last updated:**

02/03/2023

[View](/bg/documents/product-information/maviret-epar-product-information_bg.pdf)

español (ES) (627.47 KB - PDF)

**First published:**

17/08/2017

**Last updated:**

02/03/2023

[View](/es/documents/product-information/maviret-epar-product-information_es.pdf)

čeština (CS) (638.57 KB - PDF)

**First published:**

17/08/2017

**Last updated:**

02/03/2023

[View](/cs/documents/product-information/maviret-epar-product-information_cs.pdf)

dansk (DA) (573.09 KB - PDF)

**First published:**

17/08/2017

**Last updated:**

02/03/2023

[View](/da/documents/product-information/maviret-epar-product-information_da.pdf)

Deutsch (DE) (651.2 KB - PDF)

**First published:**

17/08/2017

**Last updated:**

02/03/2023

[View](/de/documents/product-information/maviret-epar-product-information_de.pdf)

eesti keel (ET) (585.63 KB - PDF)

**First published:**

17/08/2017

**Last updated:**

02/03/2023

[View](/et/documents/product-information/maviret-epar-product-information_et.pdf)

ελληνικά (EL) (619.93 KB - PDF)

**First published:**

17/08/2017

**Last updated:**

02/03/2023

[View](/el/documents/product-information/maviret-epar-product-information_el.pdf)

français (FR) (607.7 KB - PDF)

**First published:**

17/08/2017

**Last updated:**

02/03/2023

[View](/fr/documents/product-information/maviret-epar-product-information_fr.pdf)

hrvatski (HR) (581.62 KB - PDF)

**First published:**

17/08/2017

**Last updated:**

02/03/2023

[View](/hr/documents/product-information/maviret-epar-product-information_hr.pdf)

íslenska (IS) (544.39 KB - PDF)

**First published:**

17/08/2017

**Last updated:**

02/03/2023

[View](/is/documents/product-information/maviret-epar-product-information_is.pdf)

italiano (IT) (626.25 KB - PDF)

**First published:**

17/08/2017

**Last updated:**

02/03/2023

[View](/it/documents/product-information/maviret-epar-product-information_it.pdf)

latviešu valoda (LV) (592.78 KB - PDF)

**First published:**

17/08/2017

**Last updated:**

02/03/2023

[View](/lv/documents/product-information/maviret-epar-product-information_lv.pdf)

lietuvių kalba (LT) (571.5 KB - PDF)

**First published:**

17/08/2017

**Last updated:**

02/03/2023

[View](/lt/documents/product-information/maviret-epar-product-information_lt.pdf)

magyar (HU) (623.28 KB - PDF)

**First published:**

17/08/2017

**Last updated:**

02/03/2023

[View](/hu/documents/product-information/maviret-epar-product-information_hu.pdf)

Malti (MT) (624.01 KB - PDF)

**First published:**

17/08/2017

**Last updated:**

02/03/2023

[View](/mt/documents/product-information/maviret-epar-product-information_mt.pdf)

Nederlands (NL) (577.84 KB - PDF)

**First published:**

17/08/2017

**Last updated:**

02/03/2023

[View](/nl/documents/product-information/maviret-epar-product-information_nl.pdf)

norsk (NO) (584.06 KB - PDF)

**First published:**

17/08/2017

**Last updated:**

02/03/2023

[View](/no/documents/product-information/maviret-epar-product-information_no.pdf)

polski (PL) (629.54 KB - PDF)

**First published:**

17/08/2017

**Last updated:**

02/03/2023

[View](/pl/documents/product-information/maviret-epar-product-information_pl.pdf)

português (PT) (587.66 KB - PDF)

**First published:**

17/08/2017

**Last updated:**

02/03/2023

[View](/pt/documents/product-information/maviret-epar-product-information_pt.pdf)

română (RO) (623.18 KB - PDF)

**First published:**

17/08/2017

**Last updated:**

02/03/2023

[View](/ro/documents/product-information/maviret-epar-product-information_ro.pdf)

slovenčina (SK) (604.61 KB - PDF)

**First published:**

17/08/2017

**Last updated:**

02/03/2023

[View](/sk/documents/product-information/maviret-epar-product-information_sk.pdf)

slovenščina (SL) (576.95 KB - PDF)

**First published:**

17/08/2017

**Last updated:**

02/03/2023

[View](/sl/documents/product-information/maviret-epar-product-information_sl.pdf)

Suomi (FI) (582.01 KB - PDF)

**First published:**

17/08/2017

**Last updated:**

02/03/2023

[View](/fi/documents/product-information/maviret-epar-product-information_fi.pdf)

svenska (SV) (571.83 KB - PDF)

**First published:**

17/08/2017

**Last updated:**

02/03/2023

[View](/sv/documents/product-information/maviret-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** IB/0055 02/03/2023

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Maviret : EPAR - All Authorised presentations

English (EN) (30.82 KB - PDF)

**First published:** 17/08/2017

**Last updated:** 01/09/2021

[View](/en/documents/all-authorised-presentations/maviret-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-200)

български (BG) (34.09 KB - PDF)

**First published:**

17/08/2017

**Last updated:**

01/09/2021

[View](/bg/documents/all-authorised-presentations/maviret-epar-all-authorised-presentations_bg.pdf)

español (ES) (31.39 KB - PDF)

**First published:**

17/08/2017

**Last updated:**

01/09/2021

[View](/es/documents/all-authorised-presentations/maviret-epar-all-authorised-presentations_es.pdf)

čeština (CS) (31.06 KB - PDF)

**First published:**

17/08/2017

**Last updated:**

01/09/2021

[View](/cs/documents/all-authorised-presentations/maviret-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (31.38 KB - PDF)

**First published:**

17/08/2017

**Last updated:**

01/09/2021

[View](/da/documents/all-authorised-presentations/maviret-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (32.1 KB - PDF)

**First published:**

17/08/2017

**Last updated:**

01/09/2021

[View](/de/documents/all-authorised-presentations/maviret-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (31.64 KB - PDF)

**First published:**

17/08/2017

**Last updated:**

01/09/2021

[View](/et/documents/all-authorised-presentations/maviret-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (33.14 KB - PDF)

**First published:**

17/08/2017

**Last updated:**

01/09/2021

[View](/el/documents/all-authorised-presentations/maviret-epar-all-authorised-presentations_el.pdf)

français (FR) (31.12 KB - PDF)

**First published:**

17/08/2017

**Last updated:**

01/09/2021

[View](/fr/documents/all-authorised-presentations/maviret-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (30.72 KB - PDF)

**First published:**

17/08/2017

**Last updated:**

01/09/2021

[View](/hr/documents/all-authorised-presentations/maviret-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (31.37 KB - PDF)

**First published:**

17/08/2017

**Last updated:**

01/09/2021

[View](/is/documents/all-authorised-presentations/maviret-epar-all-authorised-presentations_is.pdf)

italiano (IT) (30.71 KB - PDF)

**First published:**

17/08/2017

**Last updated:**

01/09/2021

[View](/it/documents/all-authorised-presentations/maviret-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (31.43 KB - PDF)

**First published:**

17/08/2017

**Last updated:**

01/09/2021

[View](/lv/documents/all-authorised-presentations/maviret-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (32.8 KB - PDF)

**First published:**

17/08/2017

**Last updated:**

01/09/2021

[View](/lt/documents/all-authorised-presentations/maviret-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (31.36 KB - PDF)

**First published:**

17/08/2017

**Last updated:**

01/09/2021

[View](/hu/documents/all-authorised-presentations/maviret-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (32.36 KB - PDF)

**First published:**

17/08/2017

**Last updated:**

01/09/2021

[View](/mt/documents/all-authorised-presentations/maviret-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (30.29 KB - PDF)

**First published:**

17/08/2017

**Last updated:**

01/09/2021

[View](/nl/documents/all-authorised-presentations/maviret-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (31.71 KB - PDF)

**First published:**

17/08/2017

**Last updated:**

01/09/2021

[View](/no/documents/all-authorised-presentations/maviret-epar-all-authorised-presentations_no.pdf)

polski (PL) (31.98 KB - PDF)

**First published:**

17/08/2017

**Last updated:**

01/09/2021

[View](/pl/documents/all-authorised-presentations/maviret-epar-all-authorised-presentations_pl.pdf)

português (PT) (31.37 KB - PDF)

**First published:**

17/08/2017

**Last updated:**

01/09/2021

[View](/pt/documents/all-authorised-presentations/maviret-epar-all-authorised-presentations_pt.pdf)

română (RO) (31.79 KB - PDF)

**First published:**

17/08/2017

**Last updated:**

01/09/2021

[View](/ro/documents/all-authorised-presentations/maviret-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (32.05 KB - PDF)

**First published:**

17/08/2017

**Last updated:**

01/09/2021

[View](/sk/documents/all-authorised-presentations/maviret-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (31.06 KB - PDF)

**First published:**

17/08/2017

**Last updated:**

01/09/2021

[View](/sl/documents/all-authorised-presentations/maviret-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (30.62 KB - PDF)

**First published:**

17/08/2017

**Last updated:**

01/09/2021

[View](/fi/documents/all-authorised-presentations/maviret-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (24.2 KB - PDF)

**First published:**

17/08/2017

**Last updated:**

01/09/2021

[View](/sv/documents/all-authorised-presentations/maviret-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Maviret Active substance

- glecaprevir
- pibrentasvir

International non-proprietary name (INN) or common name

- glecaprevir
- pibrentasvir

Therapeutic area (MeSH) Hepatitis C, Chronic Anatomical therapeutic chemical (ATC) code J05AP57

### Pharmacotherapeutic group

Antivirals for systemic use

### Therapeutic indication

Maviret is indicated for the treatment of chronic hepatitis C virus (HCV) infection in adults and children aged 3 years and older.

Maviret coated granules is indicated for the treatment of chronic hepatitis C virus (HCV) infection in children 3 years and older.

## Authorisation details

EMA product number EMEA/H/C/004430

Accelerated assessment

This medicine had an accelerated assessment. This means that it is a medicine of major interest for public health, so its timeframe for review was 150 evaluation days rather than 210. For more information, see [Accelerated assessment](/node/69621) .

Marketing authorisation holder

AbbVie Deutschland GmbH &amp; Co. KG

Knollstrasse 67061 Ludwigshafen Germany

Opinion adopted 22/06/2017 Marketing authorisation issued 26/07/2017 Revision 23

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Maviret : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (277.58 KB - PDF)

**First published:** 06/02/2018

**Last updated:** 02/03/2023

[View](/en/documents/procedural-steps-after/maviret-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

Maviret-PAM-0000291196 : EPAR - Assessment report

Adopted

Reference Number: EMADOC-1700519818-2373718

English (EN) (1.74 MB - PDF)

**First published:** 20/11/2025

[View](/en/documents/variation-report/maviret-pam-0000291196-epar-assessment-report_en.pdf)

Maviret : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation(s)

English (EN) (101.77 KB - PDF)

**First published:** 23/08/2022

[View](/en/documents/scientific-conclusion/maviret-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations_en.pdf)

Maviret-H-C-004430-P46-011 : EPAR - Assessment report

Adopted

Reference Number: EMA/CHMP/121612/2022

English (EN) (262.91 KB - PDF)

**First published:** 21/04/2022

[View](/en/documents/variation-report/maviret-h-c-004430-p46-011-epar-assessment-report_en.pdf)

Maviret-H-C-004430-X-0033-G : EPAR - Assessment report - Variation

Adopted

Reference Number: EMA/372473/2021

English (EN) (2.93 MB - PDF)

**First published:** 28/07/2021

**Last updated:** 28/07/2021

[View](/en/documents/variation-report/maviret-h-c-004430-x-0033-g-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Maviret (X-33-G)

Adopted

Reference Number: EMA/CHMP/212239/2021

English (EN) (125.27 KB - PDF)

**First published:** 26/04/2021

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-maviret-x-33-g_en.pdf)

Maviret-PSUSA-00010620-201807 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

English (EN) (69.64 KB - PDF)

**First published:** 17/07/2019

[View](/en/documents/scientific-conclusion/maviret-psusa-00010620-201807-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

Maviret-H-C-004430-II-0012 : EPAR - Assessment report - Variation

Adopted

Reference Number: EMA/154469/2019

English (EN) (1000.22 KB - PDF)

**First published:** 24/04/2019

[View](/en/documents/variation-report/maviret-h-c-004430-ii-0012-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Maviret (II-12)

Adopted

Reference Number: EMA/CHMP/901868/2019

English (EN) (67.34 KB - PDF)

**First published:** 01/02/2019

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-maviret-ii-12_en.pdf)

## Initial marketing authorisation documents

Maviret : EPAR - Public assessment report

Adopted

Reference Number: EMA/449689/2017

English (EN) (2.65 MB - PDF)

**First published:** 17/08/2017

**Last updated:** 17/08/2017

[View](/en/documents/assessment-report/maviret-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Maviret

Adopted

Reference Number: EMA/364961/2017

English (EN) (68.01 KB - PDF)

**First published:** 23/06/2017

**Last updated:** 23/06/2017

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-maviret_en.pdf)

#### News on Maviret

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 April 2021](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-19-22-april-2021) 23/04/2021

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 28-31 January 2019](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-28-31-january-2019) 01/02/2019

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 June 2017](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-19-22-june-2017) 23/06/2017

[Two new medicines recommended for the treatment of chronic hepatitis C](/en/news/two-new-medicines-recommended-treatment-chronic-hepatitis-c-0) 23/06/2017

#### More information on Maviret

- [EMEA-001832-PIP01-15-M02 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-001832-pip01-15-m02)
- [A study to evaluate the risk of de novo hepatocellular carcinoma in patients with compensated cirrhosis treated with direct-acting antivirals for chronic hepatitis C (De Novo DAA PASS) - post-authorisation study](https://catalogues.ema.europa.eu/study/44706)
- [LICAVIR Study Synopsis and Table Shells - post-authorisation study](https://catalogues.ema.europa.eu/study/44831)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 20/11/2025

## Share this page

[Back to top](#main-content)